Trial Profile

A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipatasertib (Primary) ; Paclitaxel
Indications Adenocarcinoma; Advanced breast cancer; Triple negative breast cancer
Focus Proof of concept; Therapeutic Use
Acronyms LOTUS
Sponsors Genentech; Roche

01 Sep 2021 Results of final overall survival results of the double-blind placebo-controlled randomized phase 2 LOTUS trial, published in the Breast Cancer Research and Treatment
15 Nov 2019 Status changed from active, no longer recruiting to completed.
11 Oct 2019 This trial has been completed in France, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com